Capecitabine
- PDF / 140,433 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 20 Downloads / 134 Views
1
S
Fatty liver in an elderly patient: case report A 74-year-old woman developed fatty liver during treatment with capecitabine for stage III colon cancer. The woman, who had comorbid gastroesophageal reflux disease, hypertension and type 2 diabetes mellitus, started adjuvant chemotherapy with capecitabine 1000 mg/m2 twice daily for 14 days every three weeks, for a planned total of eight cycles [route not stated]. She had no history of hepatic disease or hepatitis B or C infection, and she did not drink alcohol. Her dosage was subsequently reduced to 750 mg/m2 twice daily after she developed diarrhoea with her first cycle; she tolerated her reduced dosage well. After her third cycle of capecitabine, her transaminase levels began to rise and, after her fourth cycle, her bilirubin level was mildly elevated. To rule out the possibility of hepatic dysfunction due to liver metastases, capecitabine was delayed until imaging results were obtained. Marked hepatomegaly with severe fatty infiltration of her liver was revealed on abdominal MRI. She was subsequently diagnosed with capecitabine–induced hepatic steatosis [time to reaction onset not clearly stated]. Capecitabine was withheld, and the woman’s transaminase and bilirubin levels normalised after 1 month. After consultation, a rechallenge with close monitoring of her liver enzymes was decided. After her first rechallenge cycle, her transaminase and bilirubin levels were normal. Author comment: "The classic findings of fatty liver associated with abnormal liver tests and the improvement in transaminases upon drug interruption render [non–alcoholic fatty liver disease] due to capecitabine the most likely diagnosis in our patient." Chin S, et al. Hepatic steatosis secondary to capecitabine: A case report. Journal of Medical Case Reports 4: No. 227, 2010. Available from: URL: http:// 803048038 dx.doi.org/10.1186/1752-1947-4-227 - Canada
0114-9954/10/1334-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 15 Jan 2011 No. 1334
Data Loading...
